Alkermes

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes, sold 7,576 shares on Aug. 17, 2026 for a weighted average price of $49.23, netting about $373,000. The sale was executed under a Rule 10b5-1 trading plan adopted May 15, 2026 and reduced his direct holdings to 102,193 shares (≈0.06% ownership). The company reported strong H1 2026 revenue growth and a 12-month stock gain, and analysts remain generally positive on Alkermes. » Więcej na finance.yahoo.com

Alkermes published Phase‑2 data from the Vibrance‑1 study in 92 adults with narcolepsy type 1. Once‑daily doses of 4, 6 or 8 mg Alixorexton produced statistically significant improvements in excessive daytime sleepiness; all dose groups achieved mean Maintenance of Wakefulness Test values of at least 20 minutes and Epworth scores of ≤10 at week 6. In the 6‑mg group the weekly cataplexy rate fell versus placebo; the drug was generally well tolerated and no serious adverse events occurred. Based on these results, a global Phase‑3 program (Brilliance Studies) is now under way; Alixorexton has received Breakthrough Therapy and Orphan Drug status in the US for certain indications. » Więcej na de.investing.com

Alkermes has agreed an amendment to its loan agreement that reduces the interest margins on its secured senior term loans. The adjustment lowers the margin on the TLA facility by 0.75 percentage points and on the TLB facility by 0.50 percentage points; TLA has an outstanding amount of USD 745.3m (maturity Feb. 12, 2031), TLB USD 773.1m (maturity Aug. 12, 2031). After the amendment, TLA will bear interest at Term SOFR plus 1.75–2.25% or Alternate Base Rate plus 0.75–1.25% depending on net leverage, and TLB at Term SOFR plus 2.25% or Alternate Base Rate plus 1.25%. The agreement was made with several lenders, including JPMorgan Chase and BofA Securities as arrangers. » Więcej na de.investing.com